Clinical Trial Update: Staccato Loxapine in Agitated Patients With Schizophrenia [Phase 3]

View source ↗

Summary

Phase 3 trial results for Staccato Loxapine in agitation associated with schizophrenia have been completed and results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Staccato Loxapine (loxapine)

Snippet

Sponsor: Alexza Pharmaceuticals, Inc. | Conditions: Patients With Schizophrenia and Acute Agitation | Phase 3 | Status: COMPLETED | Results posted: 2017-06-29